Product Description
Azeliragon is an oral, small-molecule inhibitor of RAGE, a cell-surface receptor of the immunoglobulin superfamily. (Sourced from: https://www.alzforum.org/therapeutics/azeliragon)
Mechanisms of Action: RAGE Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Orphan Drug - GlioblastomaOrphan Drug - Pancreatic Cancer *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: vTv
Company Location: HIGH POINT NC 27265
Company CEO: Paul J. Sekhri
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Spain, United States
Active Clinical Trial Count: 5
Highest Development Phases
Phase 2: Brain Cancer|Glioblastoma|Pancreatic Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2022-002801-36 | P2 |
Active, not recruiting |
Glioblastoma |
2026-03-01 |
|
ADORATION | P2 |
Recruiting |
Brain Cancer |
2025-10-01 |
|
CAN-201 MPC | P2 |
Recruiting |
Pancreatic Cancer |
2025-02-01 |
57% |
CAN 201 | P2 |
Active, not recruiting |
Glioblastoma |
2024-12-01 |